|Safety, activity, and immune correlates of anti–PD-1 antibody in cancer|
SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ...
New England Journal of Medicine 366 (26), 2443-2454, 2012
|The blockade of immune checkpoints in cancer immunotherapy|
Nature Reviews Cancer 12 (4), 252-264, 2012
|Safety and activity of anti–PD-L1 antibody in patients with advanced cancer|
JR Brahmer, SS Tykodi, LQM Chow, WJ Hwu, SL Topalian, P Hwu, ...
New England Journal of Medicine 366 (26), 2455-2465, 2012
|PD-1 blockade in tumors with mismatch-repair deficiency|
DT Le, JN Uram, H Wang, BR Bartlett, H Kemberling, AD Eyring, ...
New England Journal of Medicine 372 (26), 2509-2520, 2015
|STATs in cancer inflammation and immunity: a leading role for STAT3|
H Yu, D Pardoll, R Jove
Nature reviews cancer 9 (11), 798-809, 2009
|Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor …|
G Dranoff, E Jaffee, A Lazenby, P Golumbek, H Levitsky, K Brose, ...
Proceedings of the National Academy of Sciences 90 (8), 3539-3543, 1993
|Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates|
JR Brahmer, CG Drake, I Wollner, JD Powderly, J Picus, WH Sharfman, ...
Journal of clinical oncology 28 (19), 3167, 2010
|Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade|
DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ...
Science 357 (6349), 409-413, 2017
|Immune checkpoint blockade: a common denominator approach to cancer therapy|
SL Topalian, CG Drake, DM Pardoll
Cancer cell 27 (4), 450-461, 2015
|Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab|
SL Topalian, M Sznol, DF McDermott, HM Kluger, RD Carvajal, ...
Journal of clinical oncology 32 (10), 1020, 2014
|Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape|
JM Taube, RA Anders, GD Young, H Xu, R Sharma, TL McMiller, S Chen, ...
Science translational medicine 4 (127), 127ra37-127ra37, 2012
|Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment|
H Yu, M Kortylewski, D Pardoll
Nature Reviews Immunology 7 (1), 41-51, 2007
|Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti–PD-1 therapy|
JM Taube, A Klein, JR Brahmer, H Xu, X Pan, JH Kim, L Chen, DM Pardoll, ...
Clinical cancer research 20 (19), 5064-5074, 2014
|The Central Role of CD4+ T Cells in the Antitumor Immune Response|
K Hung, R Hayashi, A Lafond-Walker, C Lowenstein, D Pardoll, ...
The Journal of experimental medicine 188 (12), 2357-2368, 1998
|Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens|
AY Huang, P Golumbek, M Ahmadzadeh, E Jaffee, D Pardoll, H Levitsky
Science 264 (5161), 961-965, 1994
|Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis|
G Niu, KL Wright, M Huang, L Song, E Haura, J Turkson, S Zhang, ...
Oncogene 21 (13), 2000-2008, 2002
|A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses|
S Wu, KJ Rhee, E Albesiano, S Rabizadeh, X Wu, HR Yen, DL Huso, ...
Nature medicine 15 (9), 1016-1022, 2009
|Diffusion-driven mechanisms of protein translocation on nucleic acids. 1. Models and theory|
OG Berg, RB Winter, PH Von Hippel
Biochemistry 20 (24), 6929-6948, 1981
|Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells|
T Wang, G Niu, M Kortylewski, L Burdelya, K Shain, S Zhang, ...
Nature medicine 10 (1), 48-54, 2004
|Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy|
SL Topalian, JM Taube, RA Anders, DM Pardoll
Nature Reviews Cancer 16 (5), 275-287, 2016